35283-08-0

Usage

Uses

Used in Pharmaceutical Research:
(4-NITRO-PHENYL)-PROPYNOIC ACID ETHYL ESTER is used as a building block for the development of new drugs and active pharmaceutical ingredients. Its unique structure and properties make it a valuable component in the synthesis of various medicinal compounds.
Used in Organic Synthesis:
In the field of organic synthesis, (4-NITRO-PHENYL)-PROPYNOIC ACID ETHYL ESTER is used as a key intermediate for the production of a range of specialty chemicals, contributing to the creation of innovative materials and compounds.
Used in Agrochemical Production:
(4-NITRO-PHENYL)-PROPYNOIC ACID ETHYL ESTER is also utilized in the agrochemical industry, where it serves as a precursor in the synthesis of various agrochemicals, potentially leading to the development of new pesticides or other agricultural products.

InChI:InChI=1/C11H9NO4/c1-2-16-11(13)8-5-9-3-6-10(7-4-9)12(14)15/h3-4,6-7H,2H2,1H3

Upstream product

• 64-17-5 ethanol 
• 2216-24-2 3-(4-nitrophenyl)-2-propynoic acid 
• 840-44-8 rac-(R,S)-ethyl 2,3-dibromo-3-(4-nitrophenyl)propanoate 
• 636-98-6 p-nitrobenzene iodide 
• 143952-57-2 ethyl (tributylstannyl)propiolate 
• 840-44-8 2,3-dibromo-3-(4-nitro-phenyl)-propionic acid ethyl ester 
• 96129-36-1 5-amino-4-(4-nitro-phenyl)-isoxazole-3-carboxylic acid ethyl ester 
• 91348-52-6 (E)-ethyl 3-(4-nitrophenyl)-2-bromo-2-propenoate 
• 122-04-3 4-nitro-benzoyl chloride 
• 623-47-2 propynoic acid ethyl ester 
• 100-02-7 4-nitro-phenol 
• 106-96-7 propargyl bromide 
• 51738-10-4 2,2-dibromo-1-(4-nitrophenyl)ethene 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 2216-24-2 3-(4-nitrophenyl)-2-propynoic acid 
• 29285-16-3 3-(4-nitrophenyl)-3-oxopropanoic acid 
• 100-19-6 (4-nitrophenyl)ethanone 
• 10004-51-0 5-(4-nitro-phenyl)-isoxazol-3-one 
• 1350934-80-3 ethyl 2-(4-nitrophenyl)quinoline-3-carboxylate 
• 1393658-39-3 ethyl 3-(4-nitrophenyl)imidazo[2,1-a]isoquinoline-2-carboxylate 
• 42367-53-3 3-(4-nitrophenyl)prop-2-ynamide 
• 1584633-14-6 ethyl 6-(4-nitrophenyl)-2-oxo-2H-pyran-5-carboxylate 
• 133860-74-9 ethyl 2-fluoro-3-(4'-nitrophenyl)-3-oxo-propanoate 
• 24393-61-1 ethyl (E)-3-(4-nitrophenyl)-2-propenoate 

Relevant academic research and scientific papers

Gold-catalyzed partial hydrogenation of activated alkynes mediated by triphenylphosphine

Gold(I) can exhibit a cooperative effect with triphenylphosphine, accelerating the triphenylphosphine-mediated partial hydrogenation of activated alkynes. In this protocol, 3-arylpropiolates are selectively reduced to the Z -isomer when the aryl ring bears an electron-donor substituent, whereas 3-arylpropynones are reduced to the E-isomers.

Phosphine-mediated partial reduction of alkynes to form both (E)- and (Z)-alkenes

A mild, phosphine-mediated partial reduction of alkynyl carbonyls to the corresponding alkenes was developed. Tuning of the reaction conditions led to either the (E)- or (Z)-diastereomer with high selectivity. A range of alkynyl esters, amides, and ketones were reduced to form alkenes in good to high yields and with excellent functional group tolerance.

Development of new scaffolds as reversible tissue transglutaminase inhibitors, with improved potency or resistance to glutathione addition

Previous studies within our group have yielded a class of cinnamoyl-based competitive reversible inhibitors for tissue transglutaminase (TG2), with Ki values as low as 1.0 μM (compound CP4d). However, due to the electrophilic nature of their al

Enantioselective synthesis of β-fluoro-β-aryl-α-aminopentenamides by organocatalytic [2,3]-sigmatropic rearrangement

The tetramisole-promoted catalytic enantioselective [2,3]-sigmatropic rearrangement of quaternary ammonium salts bearing a (Z)-3-fluoro-3-arylprop-2-ene group generates, after addition of benzylamine, a range of β-fluoro-β-aryl-α-aminopentenamides containing a stereogenic tertiary fluorine substituent. Cyclic and acyclic nitrogen substituents as well as various aromatic substituents are tolerated, giving the β-fluoro-β-aryl-α-aminopentenamide products in up to 76% yield, 96:4 dr, and 98:2 er.

Gold-catalyzed Fluorination of Alkynyl Esters and Ketones: Efficient Access to Fluorinated 1,3-Dicarbonyl Compounds

We developed an efficient synthesis of 2-fluoro-1,3-dicarbonyl compounds using readily available alkynyl ketones or esters as starting material. The key step is the insertion of hydrogen fluoride (HF) to the gold carbene intermediate generated from cationic gold catalyzed addition of N-oxides to alkynyl ketones or esters. This method gives excellent chemical yields and regioselectivity with good functional group tolerance. (Figure presented.).

CHEMICAL COMPOUNDS

The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula Q: wherein D, L, M, W, X, Y, and Z are defined herein. The compounds of the invention are inhibitors of DNA methyltransferase (DNMT) activity - including DNMT1, DNMT3a, or DNMT3b- and are useful in the treatment of cancer and hyperproliferative diseases. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention

Preparation of arylpropynamides and their reaction with malonyl acid derivatives

Synthesis of arylpropynamides and their reactions with different malonic acid derivatives is described. Treatment of arylpropynamides with unsubstituted malonyl chloride furnished N-(3-arylprop-2-ynoyl)-6-chloro-4-hydroxy-2-oxo-2H- pyran-3-carboxamides; m

NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE

[Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is a specific cyclic group; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is —CH2—, O, —S(O)i— (i is 0 to 2), or —NR7—; R1 to R6 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

Preparation of α-bromoacrylates: One-pot procedure for the synthesis of conjugated acetylenic carboxylates from aldehydes with Ph3P/ Br3CCO2Et

We have established the optimal conditions for the Wittig reaction for synthesizing α-bromoacrylates with a high selectivity, and developed a simple and efficient one-pot procedure for preparing various conjugated acetylenic carboxylates in moderate to high yields. Georg Thieme Verlag Stuttgart.

Quinazoline compounds and pharmaceutical compositions containing them

The use of a compound of formula (I) or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, NH or NR8 where R8 is hydrogen or C1-6alkyl; Ra is a 3-quinoline group or a group of sub-formula (i) where R5, R6 and R7 are various specific organic groups, in the preparation of a medicament for use in the inhibtion of aurora 2 kinase. Novel compounds of formula (I) and pharmaceutical compositions useful in the treatment of cancer are also described and claimed.